






## Original Article

# Multinational prospective study of incidence and risk factors for central-line-associated bloodstream infections in 728 intensive care units of 41 Asian, African, Eastern European, Latin American, and Middle Eastern countries over 24 years

Victor Daniel Rosenthal MD<sup>1,2</sup> , Ruijie Yin MS<sup>1</sup> , Sheila Nainan Myatra MD<sup>3</sup> , Ziad A. Memish MD<sup>4</sup> , Camilla Rodrigues MD<sup>5</sup>, Mohit Kharbanda MD<sup>6</sup>, Sandra Liliana Valderrama-Beltran MD<sup>7</sup>, Yatin Mehta MD<sup>8</sup> , Majeda Afeef Al-Ruzzieh MD<sup>9</sup>, Guadalupe Aguirre-Avalos MD<sup>10,11</sup>, Ertugrul Guclu MD<sup>12</sup> , Chin Seng Gan MD<sup>13</sup> , Luisa Fernanda Jiménez Alvarez MD<sup>14</sup>, Rajesh Chawla MD<sup>15</sup>, Sona Hlinkova MD<sup>16,17</sup> , Rajalakshmi Arjun MD<sup>18</sup> , Hala Mounir Agha MD<sup>19</sup>, Maria Adelia Zuniga Chavarria MD<sup>20</sup>, Narangarav Davaadagva MD<sup>21</sup>, Yin Hoong Lai RN<sup>22</sup>, Katherine Gomez RN<sup>23</sup>, Daisy Aguilar De Moros RN<sup>24</sup> , Chian-Wern Tai MD<sup>25</sup> , Alejandro Sassoe Gonzalez MD<sup>26</sup>, Lina Alejandra Aguilar Moreno MD<sup>27</sup>, Kavita Sandhu MD<sup>28</sup> , Jarosław Janc MD<sup>29</sup> , Mary Cruz Aleman Bocanegra MD<sup>30</sup>, Dincer Yildizdas MD<sup>31</sup>, Yuliana Andrea Cano Medina MD<sup>32</sup> , Maria Isabel Villegas Mota MD<sup>33</sup>, Abeer Aly Omar MD<sup>34</sup>, Wieslawa Duszynska MD<sup>35</sup> , Amani Ali El-Kholy MD<sup>36</sup> , Safaa Abdulaziz Alkhwaja<sup>37</sup> , George Horhat Florin MD<sup>38,39</sup> , Eduardo Alexandrino Medeiros MD<sup>40</sup> , Lili Tao MD<sup>41</sup>, Nellie Tumu RN<sup>42</sup>, May Gamar Elanbya MD<sup>43</sup>, Reshma Dongol RN<sup>44</sup>, Vesna Mijljević MD<sup>45</sup>, Lul Raka MD<sup>46</sup>, Lourdes Dueñas MD<sup>47</sup>, Nilton Yhuri Carreazo MD<sup>48,49</sup> , Tarek Dendane MD<sup>50</sup>, Aamer Ikram MD<sup>51</sup>, Tala Kardas MS<sup>52</sup>, Michael M. Petrov MD<sup>53</sup> , Asma Bouziri MD<sup>54</sup>, Nguyen Viet Hung MD<sup>55</sup>, Vladislav Belskiy MD<sup>56</sup> , Naheed Elahi MD<sup>57</sup> , Estuardo Salgado MD<sup>58</sup> and Zhilin Jin MS<sup>1</sup>

<sup>1</sup>Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, United States, <sup>2</sup>INICC Foundation, International Nosocomial Infection Control Consortium, Miami, Florida, United States, <sup>3</sup>Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India, <sup>4</sup>King Saud Medical City, Ministry of Health, Riyadh, Kingdom of Saudi Arabia, <sup>5</sup>Pd Hinduja National Hospital And Medical Research Centre, Mumbai, India, <sup>6</sup>Desun Hospital, Kolkata, India, <sup>7</sup>Pontificia Universidad Javeriana Hospital Universitario San Ignacio, Bogota, Colombia, <sup>8</sup>Medanta The Medicity, Haryana, India, <sup>9</sup>King Hussein Cancer Center, Amman, Jordan, <sup>10</sup>Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Mexico, <sup>11</sup>Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Mexico, <sup>12</sup>Sakarya University Training and Research Hospital, Sakarya, Turkey, <sup>13</sup>University of Malaysia Medical Centre, Kuala Lumpur, Malaysia, <sup>14</sup>Clinica Universitaria Colombia, Bogota, Colombia, <sup>15</sup>Indraprastha Apollo Hospitals, New Delhi, India, <sup>16</sup>Faculty of Health, Catholic University in Ruzomberok, Ruzomberok, Slovakia, <sup>17</sup>Central Military Hospital Ruzomberok, Ruzomberok, Slovakia, <sup>18</sup>Kerala Institute of Med Sciences Health, Trivandrum, India, <sup>19</sup>Cairo University Specialized Pediatric Hospital, Cairo, Egypt, <sup>20</sup>Hospital Clinica Biblica, San Jose de Costa Rica, Costa Rica, <sup>21</sup>Intermed Hospital, Ulaanbaatar, Mongolia, <sup>22</sup>International Islamic University Malaysia, Kuantan Pahang, Malaysia, <sup>23</sup>Clinica Sebastian de Belalcazar, Cali, Colombia, <sup>24</sup>Hospital del Niño Dr José Renán Esquivel, Panama City, Panama, <sup>25</sup>Universiti Kebangsaan Malaysia Specialist Children's Hospital, Kuala Lumpur, Malaysia, <sup>26</sup>Hospital Regional de Alta Especialidad Ixtapaluca, Ixtapaluca, Mexico, <sup>27</sup>Clinica Infantil Santa María del Lago, Bogota, Colombia, <sup>28</sup>Max Super Speciality Hospital Saket Delhi, New Delhi, India, <sup>29</sup>Department of Anesthesiology and Intensive Therapy, 4th Clinical Military Hospital with Polyclinic, Wroclaw, Poland, <sup>30</sup>Hospital San Jose TecSalud, Monterrey, Nuevo León, México, <sup>31</sup>Cukurova University. Balcali Hospital, Adana, Turkey, <sup>32</sup>Instituto Del Corazon De Bucaramanga Sede Bogota, Bogota, Colombia, <sup>33</sup>Instituto Nacional de Perinatología, México DF, México, <sup>34</sup>Infection Control Directorate. Ministry of Health, Kuwait City, Kuwait, <sup>35</sup>Wroclaw Medical University. Department of Anesthesiology and Intensive Therapy, Wroclaw, Poland, <sup>36</sup>Dar Alfouad Hospital, 6th of October City, Egypt, <sup>37</sup>Salmaniya Medical Center, Manama, Bahrain, <sup>38</sup>University of Medicine and Pharmacy Victor Babes, Timisoara, Romania, <sup>39</sup>Timisoara Emergency Clinical County Hospital Romania, Timisoara, Romania, <sup>40</sup>Hospital Sao Paulo, Universidade Federal de Sao Paulo, Sao Paulo, Brazil, <sup>41</sup>Zhongshan Hospital, Fudan University, Shanghai, China, <sup>42</sup>Port Moresby General Hospital, Port Moresby, Papua, New Guinea, <sup>43</sup>National Infection control Program, Khartoum, Sudan, <sup>44</sup>Grande International Hospital, Kathmandu, Nepal, <sup>45</sup>Clinical Center of Serbia, Belgrade, Serbia, <sup>46</sup>National Institute For Public Health, Prishtina, Kosovo, <sup>47</sup>Hospital Nacional de Niños Benjamin Bloom, San Salvador, El Salvador, <sup>48</sup>Universidad Peruana de Ciencias Aplicadas, Lima, Peru, <sup>49</sup>Hospital de Emergencias Pediátricas, Lima, Peru, <sup>50</sup>Hôpital Ibn Sina, Rabat, Morocco, <sup>51</sup>National Institutes of Health, Islamabad, Pakistan, <sup>52</sup>American University of Beirut Medical Center, Beirut, Lebanon, <sup>53</sup>Medical University of Plovdiv and University Hospital "St. George," Plovdiv, Bulgaria, <sup>54</sup>Hôpital d'enfants, Tunis, Tunisia, <sup>55</sup>Bach Mai Hospital, Hanoi, Vietnam, <sup>56</sup>Privolzhskiy District Medical Center, Nizhniy Novgorod, Russia, <sup>57</sup>Dubai Hospital, Dubai, United Arab Emirates and <sup>58</sup>Hospital de Especialidades, Alianza Del Ecuador, Ecuador

**Corresponding author:** Victor D. Rosenthal, MD, Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 NW 14th Street, Floor 9, Office 912, Miami, FL 33136. E-mail: [vdr@miami.eduorvic@inicc.org](mailto:vdr@miami.eduorvic@inicc.org)

**Cite this article:** Rosenthal VD, Yin R, Myatra SN, *et al.* Multinational prospective study of incidence and risk factors for central-line-associated bloodstream infections in 728 intensive care units of 41 Asian, African, Eastern European, Latin American, and

Middle Eastern countries over 24 years. *Infect Control Hosp Epidemiol* 2023. doi: 10.1017/ice.2023.69

## Abstract

**Objective:** To identify central-line (CL)-associated bloodstream infection (CLABSI) incidence and risk factors in low- and middle-income countries (LMICs).

**Design:** From July 1, 1998, to February 12, 2022, we conducted a multinational multicenter prospective cohort study using online standardized surveillance system and unified forms.

**Setting:** The study included 728 ICUs of 286 hospitals in 147 cities in 41 African, Asian, Eastern European, Latin American, and Middle Eastern countries.

**Patients:** In total, 278,241 patients followed during 1,815,043 patient days acquired 3,537 CLABSIs.

**Methods:** For the CLABSI rate, we used CL days as the denominator and the number of CLABSIs as the numerator. Using multiple logistic regression, outcomes are shown as adjusted odds ratios (aORs).

**Results:** The pooled CLABSI rate was 4.82 CLABSIs per 1,000 CL days, which is significantly higher than that reported by the Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN). We analyzed 11 variables, and the following variables were independently and significantly associated with CLABSI: length of stay (LOS), risk increasing 3% daily (aOR, 1.03; 95% CI, 1.03–1.04;  $P < .0001$ ), number of CL days, risk increasing 4% per CL day (aOR, 1.04; 95% CI, 1.03–1.04;  $P < .0001$ ), surgical hospitalization (aOR, 1.12; 95% CI, 1.03–1.21;  $P < .0001$ ), tracheostomy use (aOR, 1.52; 95% CI, 1.23–1.88;  $P < .0001$ ), hospitalization at a publicly owned facility (aOR, 3.04; 95% CI, 2.31–4.01;  $P < .0001$ ) or at a teaching hospital (aOR, 2.91; 95% CI, 2.22–3.83;  $P < .0001$ ), hospitalization in a middle-income country (aOR, 2.41; 95% CI, 2.09–2.77;  $P < .0001$ ). The ICU type with highest risk was adult oncology (aOR, 4.35; 95% CI, 3.11–6.09;  $P < .0001$ ), followed by pediatric oncology (aOR, 2.51; 95% CI, 1.57–3.99;  $P < .0001$ ), and pediatric (aOR, 2.34; 95% CI, 1.81–3.01;  $P < .0001$ ). The CL type with the highest risk was internal-jugular (aOR, 3.01; 95% CI, 2.71–3.33;  $P < .0001$ ), followed by femoral (aOR, 2.29; 95% CI, 1.96–2.68;  $P < .0001$ ). Peripherally inserted central catheter (PICC) was the CL with the lowest CLABSI risk (aOR, 1.48; 95% CI, 1.02–2.18;  $P = .04$ ).

**Conclusions:** The following CLABSI risk factors are unlikely to change: country income level, facility ownership, hospitalization type, and ICU type. These findings suggest a focus on reducing LOS, CL days, and tracheostomy; using PICC instead of internal-jugular or femoral CL; and implementing evidence-based CLABSI prevention recommendations.

(Received 22 December 2022; accepted 15 March 2023)

As reported by the International Nosocomial Infection Control Consortium (INICC) in pooled studies, rates of central-line-associated bloodstream infection (CLABSI) have been significantly higher in low- and middle-income countries (LMICs) than in high-income countries.<sup>1–3</sup> According to a review, they ranged from 1.6 to 44.6 CLABSIs per 1,000 central-line (CL) days in adult and pediatric intensive care units (ICUs) and from 2.6 to 60.0 CLABSIs per 1,000 CL days in neonatal NICUs (NICUs).<sup>3</sup> CLABSI rates significantly increased in ICUs of LMICs during the COVID-19 pandemic.<sup>4</sup>

Multiple logistic regression identified the acquisition of a CLABSI as an independent risk factor associated with ICU all-cause mortality (adjusted odds ratio [aOR], 1.84; 95% confidence interval [CI], 1.73–1.95;  $P < .0001$ ).<sup>5</sup> This association was also demonstrated in 9 Asian countries (aOR, 2.36; 95% CI, 2.14–2.61;  $P < .0001$ )<sup>6</sup> and 10 Middle Eastern countries (aOR, 1.49; 95% CI, 1.33–1.66;  $P < .00001$ ).<sup>7</sup>

CLABSIs are associated with higher mortality by 12%–25%<sup>8</sup> and extra costs.<sup>9–12</sup> The INICC reported that mortality in ICU patients without any healthcare-associated infection (HAI) is 17.1%, with CLABSI the mortality rate is 48.2%, and mortality is 63.4% with a CLABSI plus catheter-associated urinary tract infection (CAUTI) plus ventilator-associated pneumonia (VAP).<sup>2</sup>

Previous studies have identified the following variables as CLABSI risk factors: body mass index  $>40$  kg/m<sup>2</sup>,<sup>13</sup> multiple CLs,<sup>13,14</sup> multilumen catheters,<sup>13</sup> femoral site,<sup>15,16</sup> guidewire exchange,<sup>14</sup> heavy microbial colonization at insertion site or catheter hub,<sup>13</sup> indwelling time,<sup>13</sup> prolonged hospitalization before catheterization,<sup>13</sup> neutropenia,<sup>13</sup> total parenteral nutrition,<sup>13,14</sup> patient cared for by a floating nurse,<sup>17</sup> transfusion of blood products,<sup>13</sup> prematurity,<sup>13</sup> reduced ICU nurse-to-patient ratio,<sup>13</sup> substandard CL care,<sup>13</sup> and few others.

However, no study has analyzed multiple countries or different types of vascular catheters simultaneously to identify CLABSI risk factors in ICUs. Also, no study has been conducted prospectively over 24 years. Furthermore, no study has analyzed all the following 11 variables simultaneously and their association with CLABSI: sex, age, length of stay (LOS), CL days before acquisition of CLABSI, CL device utilization (DU) ratio as a marker of severity of illness of patients, different types of vascular catheters, tracheostomy use, hospitalization type, ICU type, facility ownership, and World Bank country classifications by income level.

The objective of this study was to report CLABSI rates per country, per continent, per type of ICU, per facility ownership, per income level (according to the World Bank), and per year. We also analyzed whether these 11 variables were CLABSI risk factors, and we sought to identify the safest type of CL.

## Methods

### Study population and design

This multinational, multicenter, cohort, prospective study included patients admitted to 728 ICUs of 286 hospitals in 147 cities in 41 countries of Africa, Asia, Eastern Europe, Latin America, and the Middle East across 24 years, between July 1, 1998, and February 12, 2022.

### INICC surveillance online system

According to standard Centers for Disease Control and Prevention National Healthcare Safety Network (CDC NHSN) methods, HAI denominators are device days collected from all patients as pooled

data, without specifying each patient's characteristics or the number of device days related to such patients.<sup>18</sup> INICC HAI surveillance is carried out using an online platform, the ISOS, which includes CDC NHSN criteria and methods.<sup>18</sup> The ISOS also adds the collection of patient-specific data on all patients, with and without HAI.<sup>19</sup> Data were collected for all patients admitted to the ICU, which allowed matching by various characteristics and facilitated the estimation of CLABSI risk factors.

### Prospective cohort surveillance of healthcare-associated infections

The data were collected on each patient at the time of their ICU admission. From admission to discharge, infection prevention professionals (IPPs) went to the bedside of each patient daily. All patients admitted to an ICU were prospectively included in this investigation, and their data were collected using the INICC surveillance online system (ISOS). Each IPP used a tablet at the bedside of each hospitalized patient in the ICU, logged into the ISOS, and uploaded the patient data in real time.<sup>19</sup> At the time the patient was admitted, this information included details about the setting, country, city, admission date, and ICU type, as well as patient data, sex, age, hospitalization type, and used of invasive devices. Each IPP uploaded information about invasive devices and positive cultures until patient discharge.<sup>19</sup> In patients with signs or symptoms of infection, an infectious diseases specialist approached the patient to determine the presence of HAI.<sup>19</sup>

Each participating hospital had a microbiology laboratory that identified microorganism profiles and bacterial resistance. Furthermore, 35 patients with missing data regarding age and/or sex (0.01% of the sample) were excluded from this analysis. This study was approved by the institutional review boards of the hospitals involved. All patient and hospital identifiers were kept confidential.

### Study definitions

#### Healthcare-associated infection

Healthcare-associated infection (HAI) definitions used during surveillance were those published by Centers for Disease Control and Prevention (CDC) in 1991<sup>20</sup> and all subsequent updates.<sup>18</sup> Over the 24 years of this study, all IPPs of the participant hospitals have applied the current and updated CDC definition of HAI. That is, whenever the CDC updated their definition, IPPs began using the new updated definitions.<sup>18,20</sup>

#### Central line

A central line (CL) was defined as an intravascular catheter that terminated at or close to the heart or in one of the great vessels and was used for infusion, withdrawal of blood, or hemodynamic monitoring. The following are considered great vessels: aorta, pulmonary artery, superior or inferior vena cava, brachiocephalic veins, internal jugular veins, subclavian veins, external iliac veins, common iliac veins, femoral veins, in neonates, the umbilical artery or vein.<sup>18</sup>

#### Primary bloodstream infection

Primary bloodstream infection was defined as a laboratory-confirmed bloodstream infection (LCBI) that was not secondary to an infection at another body site.<sup>18</sup>

#### Central-line-associated bloodstream infection

Central-line-associated bloodstream infection (CLABSI) was defined as an LCBI in which an eligible BSI organism was identified and an eligible CL was present on or the day before.<sup>18</sup>

#### Laboratory-confirmed bloodstream infection 1

This term was used in a patient of any age who had a recognized bacterial or fungal pathogen not included on the NHSN common commensal list. This pathogen was identified from 1 or more blood specimens obtained by a culture or identified to the genus or species level by non-culture-based microbiologic testing methods. In addition, organism(s) identified in the blood were not related to an infection at another site.<sup>18</sup>

#### Laboratory-confirmed bloodstream infection 2

This term was used in a patient of any age who had at least 1 of the following signs or symptoms: fever (>38.0°C), chills, or hypotension. Also, the organism(s) identified in the blood are not related to an infection at another site, and the same NHSN common commensal is identified by culture from 2 or more blood specimens collected on separate occasions.<sup>18</sup>

#### Common commensal

Common commensal organisms included but were not limited to diphtheroids (*Corynebacterium* spp not *C. diphtheria*), *Bacillus* spp (not *B. anthracis*), *Propionibacterium* spp, coagulase-negative staphylococci (including *Staphylococcus epidermidis*), viridans-group streptococci, *Aerococcus* spp, *Micrococcus* spp, and *Rhodococcus* spp.<sup>18</sup>

#### Central-line-device utilization ratio

The central-line-device utilization ratio (CL-DU) was calculated as a ratio of CL days to patient days for each location type. As such, the CL-DU of a location measures the use of invasive devices and constitutes an extrinsic CLABSI risk factor. The CL-DU ratio also serve as a marker for the severity of illness of patients which is an intrinsic HAI risk factor.<sup>18</sup>

#### World Bank country classification by income level

The World Bank assigns the world's economies to 4 income groups: low, lower-middle, upper-middle, and high. The classifications are based on gross national income (GNI) per capita in the current US dollars. Low-income countries are those with GNI < US\$1,045. Lower-middle income countries are those with GNI from US\$1,046 to US\$4,095. Upper-middle income countries are those with GNI from US\$4,096 to US\$12,695. High-income countries are those with GNI > US\$12,695.<sup>21</sup> The inclusion of high-income countries allowed us to compare the risk factors for CLABSI among LMICs with those of high-income countries and identify if the income of the country is independently associated as a risk factor for CLABSI.

#### Facility or institution ownership type

Publicly owned facilities are owned or controlled by a governmental unit or another public corporation, where control is defined as the ability to determine the general corporate policy. Not-for-profit, privately owned facilities are legal or social entities created for the purpose of producing goods and services, whose status does not permit them to be a source of income, profit or other financial gains for the unit(s) that establish, control, or finance them. For-profit, privately owned facilities are legal entities set up for the

purpose of producing goods and services and can generate a profit or other financial gains for their owners.<sup>22</sup>

### Statistical analyses

For risk factor analysis, we conducted a case–control study nested in a prospective cohort study. Patients with and without CLABSI were compared using multiple logistic regression. Statistically significant variables were independently associated with an increased risk for CLABSI. We used the Wald test, and statistical significance was set at .05. Calculated from the outputs of multiple logistic regression, adjusted odds ratios (aORs) and the corresponding 95% CIs of statistically significant variables were also reported.

We analyzed following 11 variables and their association with CLABSI: (1) age; (2) male or female sex; (3) LOS before acquiring a CLABSI; (4) CL days before acquisition of CLABSI; (5) CL-DU ratio as a marker of severity of illness of patient; (6) different types and insertion sites of vascular catheters (ie, internal jugular, femoral, arterial, subclavian, temporary catheter for hemodialysis, peripherally inserted central catheter or PICC); (7) tracheostomy use; (8) medical or surgical hospitalization type; (9) ICU type (ie, medical-surgical, medical, pediatric, surgical, coronary, neurosurgical, cardio-thoracic, neurologic, trauma, oncology pediatric, or oncology adult); (10) facility ownership (publicly owned, not-for-profit privately owned, for-profit privately owned, and teaching hospital)<sup>22</sup>; and (11) income level per country according to the World Bank (ie, low, lower–middle, upper–middle, or high).<sup>21</sup> The evaluated outcome was the acquisition of CLABSI according to the CDC NHSN definitions.<sup>18</sup>

For analyses of CLABSI risk factors, we used data from 35 countries: Argentina, Bahrain, Brazil, Bulgaria, China, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, Egypt, El Salvador, India, Jordan, Kosovo, Kuwait, Lebanon, Malaysia, Mexico, Mongolia, Morocco, Nepal, Pakistan, Panama, Peru, Philippines, Poland, Romania, Saudi Arabia, Slovakia, Sri Lanka, Thailand, Turkey, United Arab Emirates, and Vietnam. All of these countries collected all 11 independent variables of interest: sex, age, LOS, CL days, CL-DU ratio, different types and insertion sites of vascular catheters, tracheostomy use, hospitalization type, ICU type, facility ownership, and income level per country.

For estimation of CLABSI rates, we used data from all 41 countries including the 35 countries listed above and following 6 countries that collected only CL days and CLABSI events: Greece, Macedonia, Papua New Guinea, Russia, Serbia, Tunisia.

All statistical analyses were performed using R version 4.1.3 software (R Foundation for Statistical Computing, Vienna, Austria).

### Results

From July 1, 1998, to February 12, 2022, over 24 years, a multinational, multicenter, cohort, prospective surveillance study of CLABSIs was conducted in 728 ICUs of 286 hospitals in 147 cities in 41 countries from Africa, Asia, Eastern Europe, Latin America, and the Middle East, participating in INICC. Patients admitted to Asian facilities represent 53.39% of the sample, followed by patients in Latin America (22.79%), the Middle East (21.11%), and Eastern Europe (2.71%).

In this cohort study, the length of participation of hospitals varied from 1.1 to 226.07 months (mean, 38.47; SD, 42.62). Table 1 shows data pertaining to setting and patient characteristics. Table 2 and Figure 1 show CLABSI rates per 1,000 CL days per country and per region. Table 3 shows CLABSI rates stratified

by ICU type, income level according to the World Bank, and facility ownership. Figure 2 shows CLABSI rates stratified by year.

Using multiple logistic regression, the following variables were identified as statistically significantly associated with CLABSI (Table 4): LOS, risk increasing 3% daily; number of CL days, risk increasing 4% per CL day; surgical hospitalization; tracheostomy; hospitalization at a publicly owned facility or at a teaching hospital; and hospitalization in a middle-income country. The ICU type with highest risk was adult oncology, followed by pediatric oncology, pediatric, and medical. The CL types with the highest risk were internal-jugular and femoral. PICC had the lowest risk for CLABSI.

### Discussion

Pooled rates of CLABSI in our study of 4.82 CLABSI per 1,000 CL days were similar to the pooled CLABSI rates reported by the INICC of 5.30 CLABSIs per 1,000 CL days.<sup>2</sup> Our present study, which shows CLABSI rates stratified per country and per region, contributes to the identification of countries and regions with higher and lower CLABSI rates. On the other hand, the pooled rate of CLABSI in our present study was significantly higher than that reported by the CDC NHSN of 0.8 CLABSIs per 1,000 CL days.<sup>18</sup> In this study, we detected a trend of significant reduction in the CLABSI rate per year. This CLABSI reduction rate is probably associated with INICC infection prevention interventions implemented during the last 24 years at these hospitals, which have been participating in this network of hospitals that voluntarily use the ISOS and the INICC multidimensional approach.<sup>23–29</sup> On the other hand, CLABSI rates increased twice: once in 2014 due to the addition of several new hospitals to the INICC network that had significantly higher CLABSI rates, and again in 2020 due to the COVID-19 pandemic.

The LOS was linked to a 3% daily increase in the CLABSI risk. Jeon *et al*<sup>30</sup> conducted a study to examine the role played by LOS as a CLABSI risk factor. They conducted logistic regression and observed a nonlinear increase in the hazard of BSI with increasing LOS. The association between a longer LOS and an increased risk of CLABSI can largely be explained by the increased LOS among those who have underlying morbidity and require invasive procedures.<sup>30</sup>

We detected an incremental risk of acquiring CLABSI of 4% per CL day. Rey *et al*<sup>31</sup> also found an association of CL days as a CLABSI risk factor.<sup>31</sup>

In this study, the CL type with the highest risk of CLABSI was internal jugular, followed by femoral. In contrast, Lorente *et al*<sup>15</sup> found that the femoral site had higher risk for CLABSI than the jugular site. In another study, the femoral site is safer than the jugular site in patients with tracheostomy. These findings suggest that the use of tracheostomy in addition to the jugular site leads to a higher risk than the femoral site.<sup>32</sup>

In this study, PICC was the CL with the lowest risk of CLABSI. Chopra *et al*<sup>33</sup> conducted a meta-analysis analyzing the risk of CLABSI associated with PICC compared with central venous catheters (CVCs). In their study, PICCs were associated with a lower risk of CLABSI than were CVCs (RR, 0.62; 95% CI, 0.40–0.94).<sup>33</sup> Also, Hon *et al*<sup>34</sup> conducted a meta-analysis analyzing rate of CLABSI between tunneled CVCs versus PICCs in adult home parenteral nutrition. In their study, PICC use was associated with a significantly lower rate of CLABSI (RR, 0.40; 95% CI, 0.19–0.83).<sup>34</sup>

In our study, patients admitted to adult oncology and pediatric oncology ICUs had the highest risk of CLABSI. The CL–DU ratio,



**Table 1.** Setting and Patient Characteristics<sup>a</sup>

Variable	No. (%) <sup>b</sup>
<b>Patient characteristic</b>	
Total patients	278,241
Total patients days	1,815,043
Average LOS, mean (SD)	6.52 (7.96)
<b>Sex</b>	
Male	169,134 (60.79)
Female	109,107 (39.21)
Age, mean (SD)	52.13 (23.97)
<b>Survival status</b>	
Alive	241,108 (86.65)
Death	37,133 (13.35)
<b>Patients per hospitalization type</b>	
Medical hospitalization	203,008 (72.96)
Surgical hospitalization	75,233 (27.04)
CLABSI	3,537
<b>Invasive device utilization</b>	
CL utilization ratio Mean (SD)	178,031.8 0.64 (1.64)
Total CL days Mean (SD)	777,463 4.61 (9.97)
<b>CL days per type of CL</b>	
Subclavian	307,934 (39.61)
Jugular	215,941 (27.78)
Arterial	159,715 (20.54)
Femoral	51,053 (6.57)
Hemodialysis temporary	31,745 (4.08)
PICC	11,075 (1.42)
<b>Tracheostomy use</b>	
Yes	2,374 (0.85)
No	275,867 (99.15)
<b>Setting and facilities characteristics</b>	
ICUs	728
<b>Patients admitted per type of ICU</b>	
Medical-Surgical ICU	168,690 (60.63)
Medical ICU	30,745 (11.05)
Coronary ICU	26,540 (9.54)
Pediatric ICU	15,476 (5.56)
Surgical ICU	14,839 (5.33)
Cardio-thoracic ICU	8,023 (2.88)
Neuro-Surgical ICU	5,278 (1.90)
Adult-Oncology ICU	3,107 (1.12)
Trauma ICU	2,701 (0.97)
Neurologic ICU	1,653 (0.59)
Pediatric-Oncology ICU	1,189 (0.43)
Hospitals, n	286
<b>Patients admitted per facility ownership</b>	

(Continued)

**Please add provided "Figure 1" and "Figure 2" Table 1.** (Continued)

Variable	No. (%) <sup>b</sup>
Publicly owned facilities	65,275 (23.46)
For-profit privately owned facilities	118,207 (42.48)
Teaching hospitals	82,631 (29.70)
Not-for-profit privately owned facilities	12,128 (4.36)
Cities	147
Countries	41
<b>Countries, stratified per income level according to the World Bank</b>	
Lower-middle-income country	10 (28.57)
Upper middle-income country	19 (54.29)
High-income country	6 (17.14)

Note. ICU, intensive care unit; CL, central-line; DU, device utilization; LOS, length of stay; CLABSI, central-line-associated bloodstream infection; SD, standard deviation.

<sup>a</sup>Data collected from July 1, 1998, to February 12, 2022, over 24 years.

<sup>b</sup>Data are no. (%) unless otherwise specified.

as a marker of severity of illness of patients, was highest at those types of ICUs,<sup>18</sup> which could explain why these ICUs were associated with the highest risk of CLABSI.

We also noted that publicly owned facilities and teaching hospitals had a significantly higher risk of CLABSI than for-profit privately owned facilities. This finding is consistent with a previous study conducted in NICUs, in which the CLABSI rate per 1,000 CL days at university hospitals was 14.3 (95% CI, 12.9–15.7), the CLABSI rate at publicly owned facilities was 14.6; 95% CI, 11.0–19.1, and the CLABSI rate at for-profit, privately owned facilities was 10.8 (95% CI, 8.5–13.5).<sup>35</sup>

Additionally, middle-income countries had a significantly higher risk of CLABSI than high-income countries. This finding could be explained by the likelihood of lower-quality programs in LMICs compared with high-income countries.<sup>3</sup> In a previous study conducted in NICUs, analyzing the impact of the income level of the country and CLABSI, the CLABSI rate per 1,000 CL days in low-income countries was 37.0 (95% CI, 16.0–71.8) and the CLABSI rate in upper-middle-income countries was 17.6 (95% CI, 15.3–20.2).<sup>35</sup> In another study conducted in PICUs, the CLABSI rate in LMICs was 12.4 (95% CI, 10.5–14.3) and the CLABSI rate in upper-middle-income countries was 7.0 (95% CI, 6.3–7.9).<sup>36</sup> In both studies, the higher the income level of the country, the lower the CLABSI rate.

We did not detect an association between sex and CLABSI. This finding is consistent with other studies that also did not detect such association.<sup>37</sup>

We did not detect an association between age and CLABSI, which is inconsistent with the study of Hsu et al,<sup>38</sup> who identified age >65 years as a CLABSI risk factor. We most likely did not find such an association because we controlled for 11 independent variables that were more significantly associated with CLABSI risk than age.

Some of the CLABSI risk factors identified in our study are unlikely to change, such as the income level of the country, facility ownership, hospitalization type, and ICU type. However, some of the risk factors for CLABSI we identified can be modified: CL days, LOS, use of tracheostomy and use of internal jugular or femoral lines.

**Table 2.** Central-Line-Associated Bloodstream Infections Rates Stratified per Country and per Region

Country	Patients, No. (%)	Patient Days, No.	CL days, No.	CLABSI, No.	CLABSI Rate <sup>a</sup>	95% CI
1. Argentina	23,589 (7.29)	168,234	67,222	500	7.44	7.41–7.45
2. Bahrain	1,223 (0.38)	11,205	8,053	26	3.23	3.18–3.26
3. Brazil	16,894 (5.22)	150,181	136,354	309	2.27	2.25–2.27
4. Bulgaria	991 (0.31)	9,544	7,328	53	7.23	7.17–7.29
5. China	4,323 (1.34)	35,999	18,195	41	2.25	2.23–2.27
6. Colombia	17,159 (5.30)	127,842	92,587	457	4.94	4.92–4.95
7. Costa Rica	1,468 (0.45)	6,413	5,300	6	1.13	1.10–1.16
8. Cuba	1,029 (0.32)	6,617	4,543	7	1.54	1.50–1.57
9. Dominican Republic	1,417 (0.44)	10,569	4,503	70	15.55	15.43–15.66
10. Ecuador	943 (0.29)	16,826	9,003	33	3.67	3.62–3.70
11. Egypt	5,750 (0.18)	66,521	47,401	259	5.46	5.44–5.48
12. El Salvador	1,127 (0.35)	9,811	6,727	52	7.73	7.66–7.79
13. Greece	100 (0.03)	NA	1,743	12	6.88	6.76–7.00
14. India	151,485 (46.79)	1,963,884	782,167	2,788	3.56	3.56–3.56
15. Jordan	5,105 (1.58)	39,200	17,495	117	6.69	6.64–6.72
16. Kosovo	247 (0.08)	3,462	1,607	5	3.11	3.02–3.19
17. Kuwait	7,046 (2.18)	101,688	43,188	90	2.08	2.07–2.09
18. Lebanon	6,291 (1.94)	54,448	32,449	70	2.16	2.14–2.17
19. Macedonia	3,550 (0.11)	NA	37,216	16	0.43	0.42–0.43
20. Malaysia	5,747 (1.78)	43,913	36,452	168	4.61	4.58–4.63
21. Mexico	9,001 (2.78)	69,880	66,387	480	7.23	7.20–7.25
22. Mongolia	2,457 (0.76)	23,363	10,123	33	3.26	3.22–3.29
23. Morocco	3,582 (1.11)	25,061	5,684	82	14.43	14.32–14.52
24. Nepal	2,008 (0.62)	25,806	13,335	21	1.57	1.55–1.59
25. Pakistan	713 (0.22)	5,738	5,659	162	28.63	28.48–28.76
26. Panama	947 (0.29)	8,771	8,670	97	11.19	11.11–11.25
27. Papua New Guinea	17 (0.01)	106	8	1	125	117.37–132.99
28. Peru	2,033 (0.63)	12,752	10,043	51	5.08	5.03–5.12
29. Philippines	5,479 (1.69)	33,028	11,773	92	7.81	7.76–7.86
30. Poland	1,907 (0.59)	NA	30,160	113	3.75	3.72–3.76
31. Romania	976 (0.30)	8,465	4,346	463	106.53	106.23–106.84
32. Russia	97 (0.03)	1,116	412	7	16.99	16.59–17.39
33. Saudi Arabia	27,275 (8.42)	322,683	164,966	758	4.59	4.58–4.60
34. Serbia	186 (0.06)	1,862	580	17	29.31	28.87–29.75
35. Slovakia	937 (0.29)	NA	11,200	46	4.11	4.06–4.14
36. Sri Lanka	326 (0.10)	2,398	2,210	5	2.26	2.20–2.32
37. Thailand	648 (0.20)	2,774	670	0	0	NA
38. Tunisia	221 (0.07)	1,909	651	2	3.07	2.93–3.20
39. Turkey	13,171 (4.07)	258,098	138,289	1,390	10.05	10.03–10.07
40. United Arab Emirates	384 (0.12)	53,273	387	2	5.17	4.94–5.39
41. Vietnam	4,279 (1.32)	51,644	28,067	129	4.60	4.57–4.62
<b>Region</b>						
Pooled	331,796	...	1,870,943	728	4.82	4.64–4.93
Asia	177,155 (53.39)	2,186,255	906,449	3,434	3.79	3.78–3.79
Latin America	75,606 (22.79)	587,896	411,339	2,061	5.01	5.00–5.01

(Continued)

**Table 2.** (Continued)

Country	Patients, No. (%)	Patient Days, No.	CL days, No.	CLABSI, No.	CLABSI Rate <sup>a</sup>	95% CI
Middle East	70,047 (21.11)	934,086	458,563	2,795	6.10	6.08–6.10
Eastern Europe	8,988 (2.71)	NA	94,592	728	7.70	7.67–7.71

Note. CL, central line; DU, device utilization; CLABSI, central-line-associated bloodstream infection; CI, confidence interval.

<sup>a</sup>Rate of CLABSI per 1,000 CL days.

**Table 3.** Central-Line-Associated Bloodstream Infections Rates Stratified per ICU Type, According to World Bank Country Classifications by Income Level and Facility Ownership Type

Variable	Patients, No.	Patient Days, No.	CL Days, No.	CLABSI, No.	CLABSI Rate	95% CI
<b>ICU type<sup>a</sup></b>						
Pooled	282,793	1,845,988	1,241,905	3,685	2.97	2.96–2.97
Adult-oncology	3,472	16,872	9,464	72	7.61	7.55–7.66
Pediatric-oncology	1,509	9,342	5,493	27	4.92	4.85–4.97
Pediatric	15,751	121,343	57,935	307	5.30	5.28–5.31
Medical	31,440	221,455	112,847	391	3.46	3.45–3.47
Neurologic	1,667	11,423	4,532	15	3.31	3.25–3.36
Medical-surgical	170,950	1,118,379	743,216	2,360	3.18	3.17–3.17
Neuro-surgical	5,627	36,280	14,769	38	2.57	2.54–2.59
Cardio-thoracic	8,099	47,766	49,217	109	2.21	2.20–2.22
Surgical	14,924	98,097	72,544	150	2.07	2.05–2.07
Trauma	2,707	12,979	5,780	10	1.73	1.69–1.76
Coronary	26,647	152,052	166,108	206	1.24	1.23–1.24
<b>Lower-middle income</b>						
Pooled	151,858	874,822	650,949	1,700	2.61	2.60–2.61
Publicly owned facilities	1,507	85,692	65,101	272	4.18	4.16–4.19
For-profit privately owned facilities	13,999	425,814	236,278	754	3.19	3.18–3.19
Teaching hospitals	51,704	303,826	322,562	622	1.93	1.92–1.93
Not-for-profit privately owned facilities	10,860	247,750	174,000	857	4.93	4.91–4.93
<b>Upper-middle income</b>						
Pooled	96,388	662,350	423,291	1,582	3.74	3.73–3.74
Publicly owned facilities	21,425	152,818	114,948	402	3.50	3.48–3.50
For-profit privately owned facilities	41,998	252,252	126,853	314	2.48	2.46–2.48
Teaching hospitals	31,589	247,750	174,000	857	4.93	4.91–4.93
Not-for-profit privately owned facilities	1,376	9,530	7,490	9	1.20	1.17–1.22
<b>High income</b>						
Pooled	34,547	308,816	167,665	403	2.40	2.39–2.41
Publicly owned facilities	30,706	274,659	137,478	351	2.55	2.54–2.56
Teaching hospitals	1,253	11,615	16,040	34	2.12	2.09–2.14
For-profit privately owned facilities	2,588	22,542	14,147	18	1.27	1.25–1.29

Note.

ICU, intensive care unit; CI, confidence interval.

<sup>a</sup>ICUs are listed in order of the highest to lowest central-line-associated bloodstream infection (CLABSI) rate.

Based on our findings, we should focus on strategies to reduce CL use, reduce LOS, prefer PICC instead of internal jugular or femoral insertion, and implement an evidence-based set of CLABSI prevention recommendations, such as those recently published by the Society for Healthcare Epidemiology of America (SHEA), Association for Professionals in Infection Control and

Epidemiology (APIC), and the Infectious Diseases Society of America (IDSA).<sup>13</sup> Also, the very high rate of CLABSI prevalent in LMICs<sup>1–4</sup> can be reduced by utilizing a strategy of monitoring compliance with recommendations and providing performance feedback to healthcare personnel, as has been demonstrated in several LMICs.<sup>23–29</sup>

**Table 4.** Multiple Logistic Regression Analysis of Risk Factors for Central-Line–Associated Bloodstream Infections

Variable	aOR	95% CI	P Value
(1) Age	1.00	0.99–1.00	<.0001
(2) Sex, male	1.05	0.98–1.13	.17
(3) Length of stay	1.03	1.03–1.04	<.0001
(4) CL days	1.04	1.03–1.04	<.0001
(5) CL-DU ratio	0.91	0.89–0.93	<.0001
(6) Surgical hospitalization	1.12	1.03–1.21	<.0001
<b>(7) Vascular catheter/insertion site</b>			
Internal jugular	3.01	2.71–3.33	<.0001
Femoral	2.29	1.96–2.68	<.0001
Subclavian	2.13	1.92–2.36	<.0001
Arterial	1.89	1.69–2.13	<.0001
Hemodialysis temporary	1.84	1.41–2.39	<.0001
PICC	1.48	1.02–2.18	.04
(8) Tracheostomy use	1.52	1.23–1.88	<.0001
<b>(9) ICU type</b>			
Adult-oncology ICU	4.35	3.11–6.09	<.0001
Pediatric-oncology ICU	2.51	1.57–3.99	<.0001
Pediatric ICU	2.34	1.81–3.01	<.0001
Medical ICU	2.04	1.61–2.59	<.0001
Medical-surgical ICU	1.93	1.56–2.39	<.0001
Surgical ICU	1.43	1.09–1.87	.01
Coronary ICU	0.86	0.65–1.14	.29
Neurosurgical ICU	0.99	0.67–1.14	.98
Neurologic ICU	1.64	0.91–2.96	.11
Trauma ICU	0.85	0.43–1.71	.66
<b>(10) Facility ownership</b>			
Publicly owned facilities	3.04	2.31–4.01	<.0001
Teaching hospitals	2.91	2.22–3.83	<.0001
For-profit privately owned facilities	2.01	1.52–2.63	<.0001
<b>(11) Income level classification according with World Bank</b>			
Upper–middle-income country	2.41	2.09–2.77	<.0001
Lower–middle-income country	2.23	1.93–2.58	<.0001

Note. CI, confidence interval; CL, central line; DU, device utilization; ICU, intensive care unit; LOS, length of stay; CLABSI, central-line–associated bloodstream infection; aOR, adjusted odds ratio.

Our study had several limitations. First, because this study was part of a surveillance system in which hospitals voluntarily participated for free; thus, these findings are not representative of all hospitals in LMICs. Second, changes in personal or professional practices may have influenced risk over time. Third, changes to CLABSI definitions made by the CDC that we adopted immediately may have influenced outcomes. Fourth, the unequal contribution of data by the participating hospitals may have affected these findings. Fifth, more clinical and epidemiological data as well as water quality could be useful to characterize the situation. Finally, the IPPs of the participating hospitals did not collect information on disease severity scores; instead, we used the CL-DU ratio to assess the severity of illness, and we adjusted the analysis to account for this independent variable.

#### Acknowledgments.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors declare that they do not have any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. All authors declare that do not have potential competing interests, such as employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding.



## References

- Rosenthal VD, Maki DG, Salomao R, *et al.* Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Ann Intern Med* 2006;145:582–591.
- Rosenthal VD, Duszynska W, Ider BE, *et al.* International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2013–2018, adult and pediatric units, device-associated module. *Am J Infect Control* 2021;49:1267–1274.
- Rosenthal VD. Central-line-associated bloodstream infections in limited-resource countries: a review of the literature. *Clin Infect Dis* 2009;49:1899–1907.
- Rosenthal VD, Myatra SN, Divatia JV, *et al.* The impact of COVID-19 on healthcare-associated infections in intensive care units in low- and middle-income countries: International Nosocomial Infection Control Consortium (INICC) findings. *Int J Infect Dis* 2022.
- Rosenthal VD, Yin R, Lu Y, *et al.* The impact of healthcare-associated infections on mortality in ICU: a prospective study in Asia, Africa, Eastern Europe, Latin America, and the Middle East. *Am J Infect Control* 2022.
- Rosenthal VD, Jin Z, Rodrigues C, *et al.* Risk factors for mortality over 18 years in 317 ICUs in 9 Asian countries: the impact of healthcare-associated infections. *Infect Control Hosp Epidemiol* 2022. doi: 10.1017/ice.2022.245.
- Rosenthal VD, Jin Z, Memish ZA, *et al.* Risk factors for mortality in ICU patients in 10 Middle Eastern countries: The role of healthcare-associated infections. *J Crit Care* 2022;72:154149.
- Centers for Disease C, Prevention. Vital signs: central-line-associated bloodstream infections—United States, 2001, 2008, and 2009. *Morb Mortal Wkly Rep* 2011;60:243–248.
- Stone PW, Braccia D, Larson E. Systematic review of economic analyses of healthcare-associated infections. *Am J Infect Control* 2005;33:501–509.
- Rosenthal VD, Guzman S, Migone O, Crnich CJ. The attributable cost, length of hospital stay, and mortality of central-line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. *Am J Infect Control* 2003;31:475–480.
- Higuera F, Rangel-Frausto MS, Rosenthal VD, *et al.* Attributable cost and length of stay for patients with central venous catheter-associated bloodstream infection in Mexico City intensive care units: a prospective, matched analysis. *Infect Control Hosp Epidemiol* 2007;28:31–35.
- Tarricone R, Torbica A, Franzetti F, Rosenthal VD. Hospital costs of central-line-associated bloodstream infections and cost-effectiveness of closed vs open infusion containers. The case of intensive care units in Italy. *Cost Eff Resour Alloc* 2010;8:8.
- Buetti N, Marschall J, Drees M, *et al.* Strategies to prevent central-line-associated bloodstream infections in acute-care hospitals: 2022 update. *Infect Control Hosp Epidemiol* 2022;43:553–569.
- Almuneef MA, Memish ZA, Balkhy HH, Hijazi O, Cunningham G, Francis C. Rate, risk factors and outcomes of catheter-related bloodstream infection in a paediatric intensive care unit in Saudi Arabia. *J Hosp Infect* 2006;62:207–213.
- Lorente L, Henry C, Martin MM, Jimenez A, Mora ML. Central venous catheter-related infection in a prospective and observational study of 2,595 catheters. *Crit Care* 2005;9:R631–R635.
- O'Horo JC, Maki DG, Krupp AE, Safdar N. Arterial catheters as a source of bloodstream infection: a systematic review and meta-analysis. *Crit Care Med* 2014;42:1334–1339.
- Alonso-Echanove J, Edwards JR, Richards MJ, *et al.* Effect of nurse staffing and antimicrobial-impregnated central venous catheters on the risk for bloodstream infections in intensive care units. *Infect Control Hosp Epidemiol* 2003;24:916–925.
- Dudeck MA, Edwards JR, Allen-Bridson K, *et al.* National Healthcare Safety Network report, data summary for 2013, device-associated module. *Am J Infect Control* 2015;43:206–221.
- Rosenthal VD. International Nosocomial Infection Control Consortium (INICC) resources: INICC multidimensional approach and INICC surveillance online system. *Am J Infect Control* 2016;44:e81–e90.
- Emori TG, Culver DH, Horan TC, *et al.* National nosocomial infections surveillance system (NNIS): description of surveillance methods. *Am J Infect Control* 1991;19:19–35.
- New World Bank country classifications by income level: 2021–2022. World Bank website. <https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2021-20222022>. Published 2022. Accessed April 14, 2023.
- Glossary of terms. WHO European Primary Health Care Impact Performance and Capacity Tool (PHC-IMPACT). World Health Organization website. <https://apps.who.int/iris/handle/10665/346481>. Accessed April 14, 2023.
- Higuera F, Rosenthal VD, Duarte P, Ruiz J, Franco G, Safdar N. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico. *Crit Care Med* 2005;33:2022–2027.
- Rosenthal VD, Maki DG, Rodrigues C, *et al.* Impact of International Nosocomial Infection Control Consortium (INICC) strategy on central-line-associated bloodstream infection rates in the intensive care units of 15 developing countries. *Infect Control Hosp Epidemiol* 2010;31:1264–1272.
- Rosenthal VD, Ramachandran B, Villamil-Gomez W, *et al.* Impact of a multidimensional infection control strategy on central-line-associated bloodstream infection rates in pediatric intensive care units of five developing countries: findings of the International Nosocomial Infection Control Consortium (INICC). *Infection* 2012;40:415–423.
- Jaggi N, Rodrigues C, Rosenthal VD, *et al.* Impact of an International Nosocomial Infection Control Consortium multidimensional approach on central-line-associated bloodstream infection rates in adult intensive care units in eight cities in India. *Int J Infect Dis* 2013;17:e1218–e1224.
- Leblebicioglu H, Ozturk R, Rosenthal VD, *et al.* Impact of a multidimensional infection control approach on central-line-associated bloodstream infection rates in adult intensive care units of 8 cities of Turkey: findings of the International Nosocomial Infection Control Consortium (INICC). *Ann Clin Microbiol Antimicrob* 2013;12:10.
- Rosenthal VD, Duenas L, Sobreyra-Oropeza M, *et al.* Findings of the International Nosocomial Infection Control Consortium (INICC), part III: effectiveness of a multidimensional infection control approach to reduce central-line-associated bloodstream infections in the neonatal intensive care units of 4 developing countries. *Infect Control Hosp Epidemiol* 2013;34:229–237.
- Alvarez-Moreno CA, Valderrama-Beltran SL, Rosenthal VD, *et al.* Multicenter study in Colombia: impact of a multidimensional International Nosocomial Infection Control Consortium (INICC) approach on central-line-associated bloodstream infection rates. *Am J Infect Control* 2016;44:e235–e241.
- Jeon CY, Neidell M, Jia H, Sinisi M, Larson E. On the role of length of stay in healthcare-associated bloodstream infection. *Infect Control Hosp Epidemiol* 2012;33:1213–1218.
- Rey C, Alvarez F, De-La-Rua V, *et al.* Intervention to reduce catheter-related bloodstream infections in a pediatric intensive care unit. *Intensive Care Med* 2011;37:678–685.
- Lorente L, Jimenez A, Naranjo C, *et al.* Higher incidence of catheter-related bacteremia in jugular site with tracheostomy than in femoral site. *Infect Control Hosp Epidemiol* 2010;31:311–313.
- Chopra V, O'Horo JC, Rogers MA, Maki DG, Safdar N. The risk of bloodstream infection associated with peripherally inserted central catheters compared with central venous catheters in adults: a systematic review and meta-analysis. *Infect Control Hosp Epidemiol* 2013;34:908–918.
- Hon K, Bihari S, Holt A, Bersten A, Kulkarni H. Rate of catheter-related bloodstream infections between tunneled central venous catheters versus peripherally inserted central catheters in adult home parenteral nutrition: a meta-analysis. *J Parenter Enteral Nutr* 2019;43:41–53.
- Rosenthal VD, Lynch P, Jarvis WR, *et al.* Socioeconomic impact on device-associated infections in limited-resource neonatal intensive care units: findings of the INICC. *Infection* 2011;39:439–450.
- Rosenthal VD, Jarvis WR, Jamulitrat S, *et al.* Socioeconomic impact on device-associated infections in pediatric intensive care units of 16 limited-resource countries: international Nosocomial Infection Control Consortium findings. *Pediatr Crit Care Med* 2012;13:399–406.

37. Dahan M, O'Donnell S, Hebert J, *et al*. CLABSI RISK FACTORS in the NICU: potential for prevention: a PICNIC study. *Infect Control Hosp Epidemiol* 2016;37:1446–1452.
38. Hsu JF, Chang HL, Tsai MJ, *et al*. Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli. *World J Surg Oncol* 2015;13:288.